Location History:
- 8000 Munich 22, DE (1979)
- Munich, DE (1980 - 1992)
- D 82319 Starnberg, DE (2000)
- München, DE (2004)
Company Filing History:
1 out of 12,164 
4 out of 832,880 Years Active: 1979-2004
Title: Innovator Anton Mayr: Pioneering Advances in Immunity
Introduction
Anton Mayr, an esteemed inventor based in Munich, Germany, has made significant strides in the field of immunology. With a portfolio of five patents, he focuses on developing innovative medicaments that harness the potential of poxvirus components to enhance paramunization in medical applications.
Latest Patents
Among his latest contributions are groundbreaking patents involving paramunity inducers derived from poxvirus components. One notable invention details a method for creating multipotent paramunity inducers that exhibit enhanced potency and paramunization-related activities compared to existing alternatives. Furthermore, he has revealed the use of multipotent parapox immunity inducers, which are derived from attenuated, non-immunogenic pox or parapox viruses, for developing medicaments with novel indications in human medicine.
Career Highlights
Throughout his career, Anton Mayr has collaborated with prestigious companies, including Bayer Aktiengesellschaft, where he contributed to research initiatives that combined his expertise in immunology with practical applications in healthcare. His innovative approach has positioned him as a leader in the field, focusing on improving human health through groundbreaking inventions.
Collaborations
Anton has worked alongside distinguished colleagues such as Peter A Bachmann and Helmut Stickl. Their collaborative efforts have led to numerous developments in the realm of paramunization, fostering an environment of innovation and progress in medicinal applications.
Conclusion
Anton Mayr's work exemplifies the spirit of innovation in the scientific community. His latest patents, particularly those centered around paramunity inducers, highlight his commitment to advancing medical treatments and improving patient health outcomes. Through his career and collaborations, Mayr continues to carve out a legacy that significantly impacts the future of immunology and therapeutics.